

the following has become a member of IPACT-II: Northern Healthcare Limited Harlow, Essex, England. The Restated Formation Agreement become effective on May 8, 1995, and supersedes the prior agreement under which the Consortium operated. The only significant change in IPACT-II created by the new Agreement is that membership in IPACT-II is now open to any party that (1) has a commercial interest in pharmaceutical aerosols and (2) undertakes to pay its share of IPACT-II costs.

No other changes have been made in either the membership or planned activity of IPACT-II. Membership in this group research project is open, and IPACT-II intends to file additional written notification disclosing all changes in membership.

On February 21, 1991, IPACT-II filed its original notification pursuant to Section 6(a) of the Act. The Department of Justice published a notice in the Federal Register pursuant to Section 6(b) of the Act on April 2, 1991 (56 FR 13489).

The last notification was filed with the Department on January 14, 1993. A notice was published in the Federal Register pursuant to Section 6(b) of the Act on April 27, 1993 (58 FR 25657).

Constance K. Robinson,

Director of Operations, Antitrust Division.

[FR Doc. 96-10264 Filed 4-24-96; 8:45 am]

BILLING CODE 4410-01-M

Notice Pursuant to the National Cooperative Research and Production Act of 1993—International Pharmaceutical Aerosol Consortium for Toxicology Testing of HFA-134a (IPACT-I)

Notice is hereby given that, on May 25, 1995, pursuant to Section 6(a) of the National Cooperative Research and Production Act of 1993, 15 U.S.C. § 4301 *et seq.* ("the Act"), The International Pharmaceutical Aerosol Consortium for Toxicology Testing of HFA-134a ("IPACT-I") has filed written notifications simultaneously with the Attorney General and the Federal Trade Commission disclosing (1) a Restated IPACT-I Formation Agreement and (2) the addition of a new member. The notifications were filed for the purpose of extending the Act's provisions limiting the recovery of antitrust plaintiffs to actual damages under specified circumstances. Specifically, the following has become a new member to the IPACT-I: TAP Holdings, Inc., Deerfield, IL. The Restated Formation Agreement became effective on May 8, 1995, and

supersedes the prior agreement under which the Consortium operated. The only significant change created by the new Agreement is that membership in IPACT-I is now open to any party that: (1) has a commercial interest in pharmaceutical aerosols, and (2) undertakes to pay its share of IPACT-I costs.

No other changes have been made in either the membership or planned activity of IPACT-I. Membership in this group research project remains open, and IPACT-I intends to file additional written notification disclosing all changes in membership.

On August 7, 1990, IPACT-I filed its original notification pursuant to Section 6(a) of the Act. The Department of Justice published a notice in the Federal Register pursuant to Section 6(b) of the Act on September 6, 1990 (55 Fed. Reg. 36710).

The last notification was filed with the Department on January 14, 1993. A notice was published in the Federal Register pursuant to Section 6(b) of the Act on April 27, 1993 (58 FR 25657).

Constance K. Robinson,

Director of Operations, Antitrust Division.

[FR Doc. 96-10265 Filed 4-24-96; 8:45 am]

BILLING CODE 4410-01-M

Notice Pursuant to the National Cooperative Research and Production Act of 1993; Industrial Macromolecular Crystallography Association ("IMCA")

Notice is hereby given that on April 8, 1996, pursuant to Section 6(a) of the National Cooperative Research and Production Act of 1993, 15 U.S.C. § 4301 *et seq.* ("the Act"), Industrial Macromolecular Crystallography Association (IMCA) has filed written notifications simultaneously with the Attorney General and the Federal Trade Commission disclosing changes in its membership status. The notifications were filed for the purpose of extending the Act's provisions limiting the recovery of antitrust plaintiffs to actual damages under specified circumstances. Specifically, Sanofi Winthrop, Inc., New York, NY, has withdrawn as a member and Schering-Plough Research Institute, a corporation of Delaware, with its principal place of business in Kenilworth, NJ, has become a member. In addition, two members have changed their legal names: Glaxo, Inc., has changed its name to Glaxo Wellcome, Inc., Research Triangle Park, NC and Miles, Inc., has changed its name to Bayer Corporation, Pittsburgh, PA.

No other changes have been made in either the membership or planned activity of the group research project.

Membership in this group research project remains open, and IMCA intends to file additional written notification disclosing all changes in membership.

On October 23, 1990, IMCA filed its original notification pursuant to Section 6(a) of the Act. The Department of Justice published a notice in the Federal Register pursuant to Section 6(b) of the Act on December 3, 1990 (55 FR 49953).

The last notification was filed with the Department on January 19, 1995. A notice was published in the Federal Register pursuant to Section 6(b) of the Act on December 21, 1995 (60 FR 66324).

Constance K. Robinson,

Director of Operations, Antitrust Division.

[FR Doc. 96-10266 Filed 4-24-96; 8:45 am]

BILLING CODE 4410-01-M

Federal Bureau of Investigation

Criminal Justice Information Services (CJIS) Advisory Policy Board

The Criminal Justice information Services (CJIS) Advisory Policy Board will meet on June 12-13, 1996, from 9 a.m. until 5 p.m., at the Holiday Inn Downtown/Riverfront, 200 North Fourth Street, St. Louis, Missouri, telephone 314-621-8200, to formulate recommendations to the Director, Federal Bureau of Investigation (FBI) on the security, policy and operation of the National Crime Information Center (NCIC), NCIC 2000, the Integrated Automated Fingerprint Identification System (IAFIS), and the Uniform Crime Reporting (UCR) and National Incident Based Reporting System (NIBRS) programs.

The topics to be discussed will include the progress of the NCIC 2000 and IAFIS projects, status of the Brady Handgun Violence Prevention Act, and other topics related to the management of the FBI's criminal history information systems.

The meeting will be open to the public on a first-come, first-seated basis. Any member of the public may file a written statement concerning the FBI CJIS Division programs or related matters with the Board, before or after. Anyone wishing to address this session of the meeting should notify the Designated Federal Employee, at least 24 hours prior to the start of the session. The notification may be by mail, telegram, cable, facsimile, or a hand-delivered note. It should contain the requestor's name; corporate designation, consumer affiliation, or Government designation; along with a short statement describing the topic to be addressed; and the time needed for